Andere Sprachen Outlook Therapeutics, Inc.

Aktien

A4046T

US69012T3059

OTLK

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
8,6 ^USD	+1,18 %		+2,02 %	+9,14 %

27.03.	Outlook Therapeutics-Aktien steigen nach BTIG-Upgrade	MT
27.03.	OUTLOOK THERAPEUTICS, INC. : Von BTIG zum Kaufen aufgerüstet	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Outlook Therapeutics® to Present at the Retina World Congress 2024	02.05.
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29.04.
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16.04.
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	15.04.
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15.04.
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15.04.
Corporate Presentation: March 2024	28.03.
North American Morning Briefing : Stocks Set for -2-	28.03.
Outlook Therapeutics Shares Rise After BTIG Upgrade	27.03.
Outlook Therapeutics Reports Secondary Share Offering	25.03.
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	25.03.
Sector Update: Health Care Stocks Ease Late Afternoon	22.03.
Sector Update: Health Care Stocks Ease Friday Afternoon	22.03.
Sector Update: Health Care Stocks Steady Pre-Bell Friday	22.03.
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	22.03.
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22.03.
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22.03.
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -	19.03.
Outlook Therapeutics lève 60 millions de dollars pour l'approbation de son bevacizumab	19.03.
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Outlook Therapeutics, Inc.

Aktien

A4046T

US69012T3059

OTLK

Andere Sprachen

Filter